tbuckley/cabot-search huggingface dataset:
Lettsom: His Life, Times, Friends and Descendants
Journal: JAMA (1934)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
MYONEURAL JUNCTION ABNORMALITY IN MUSCULAR DYSTROPHY
Journal: JAMA (1964)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Abstract 4396: Gli, not Androgen Receptor, is the primary driver of prostate cell growth
Authors: Jane Foo, Na Li, Shabnam Massah, Mannan Nouri, Mike Wang, Ralph Buttyan
Journal: Cancer Research (2019)

Abstract Introduction Hedgehog (Hh) signaling regulates the activity of Gli transcription factors. Gli controls genes needed for development, cell growth and cell motility. Canonical Hh signaling through Smoothened [Smo] suppresses the proteolysis of Gli2 and Gli3, maintaining them in high molecular weight active forms. Previously, we showed that active androgen receptors ([AR] liganded AR full length and AR-V7) recognize and binds Gli3 its Protein Processing Domain. This binding overrides the need for Smo action and provides a means for stabilization and activation of Gli3 in prostate cancer (PCa) cells without Hh. Studies on the effects of AR binding to Gli2 are more challenging because it is expressed at much lower levels than Gli3. Here, we report that AR also affects Gli2 protein stability and show that Gli2, like Gli3, is a driver of PCa cell growth that is overexpressed in castration resistant disease. Method Immunohistochemistry (IHC) using Gli2- and Gli3-specific antibodies was used to assess expression of Gli2 and Gli3 in human PCa tumor microarrays. Western blot were used to identify and quantify levels of active Gli2 and Gli3 in androgen-treated PCa cells (LNCaP, LNCaP-AI, LAPC4). Proximity ligation assays (PLA) was used to visualize in situ and quantify AR-Gli2 complexes in PCa cells. Gli2- and Gli3-specific siRNAs were used to knock down Gli expression in AR+ (LNCaP-AI, LAPC4, 22Rv1) and AR- (PC3) PCa, cells followed by the Gli reporter assay and the cell growth assay. Results IHC outcomes showed that nuclear Gli2 and Gli3 protein expression was significantly higher in castration resistant tumors compared to primary disease. Androgens increased expression of active Gli2 and Gli3 protein expression in PCa cells and stimulated Gli reporter activity. PLA showed the presence of intranuclear complexes of Gli2/Gli3-AR-Full-length in androgen-treated LNCaP and Gli2-AR-V7 complexes in CWR22rv1 cells. Knockdown of Gli2 or Gli3 present significant reduction in Gli transcriptional activity as well as inhibition on growth of both AR+ and AR- PCa cells that were tested. Conclusion AR activity affects Gli2 processing, as it does for Gli3. We can visualize and quantify AR-Gli2/Gli3 complexes in situ in PCa cells. Gli2 suppression, as well as Gli3 suppression, has a profound effect on PCa cell growth but combined suppression has the strongest effects in certain PCa cells. Finally, Gli2 and Gli3 protein expression is elevated in castration resistant disease. Citation Format: Jane Foo, Na Li, Shabnam Massah, Mannan Nouri, Mike Wang, Ralph Buttyan. Gli, not Androgen Receptor, is the primary driver of prostate cell growth [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 4396.
Association News
Authors: Frank Billings
Journal: JAMA (1923)

<h3>MEETINGS OF THE BOARD OF TRUSTEES</h3> The Board of Trustees of the American Medical Association met at the Palace Hotel, San Francisco, at 4 p. m., Saturday, June 23, and meetings were held daily until after the final adjournment of the House of Delegates. The following, among other business, was transacted: <h3>Pathologists Protest Against Advertising of Commercial Laboratories in The Journal</h3> A protest from the American Society of Clinical Pathologists in regard to the advertisement of commercial laboratories inThe Journalwas presented to the Board at its first meeting. It was voted to postpone action, however, until representatives of the society presenting the protest could be present. The matter was again brought up at the meeting of the Board held in the Civic Center Auditorium at 3 p. m., June 26. A committee consisting of Dr. Philip Hillkowitz, president; Dr. William C. MacCarty, vice president, and Dr. E. A.
Erratum
Authors: A Harrower, Frcpe Railton
Journal: Diabetes Care (1997)

fibrosis, etc., and is in many cases complicated by diffuse coronary artery disease.The increased early and late mortality after myocardial infarction and the increased incidence of left ventricular failure in diabetic patients could be explained by impaired compliance of the myocardium in response to acute ischemic stress with such regional wall motion abnormalities, potentially making even minor ischemic challenges life threatening.While reduction in risk factors, such as smoking and lipid abnormalities, may reduce the incidence of coronary artery disease in diabetic subjects, it seems likely that heart disease will remain common if metabolic factors play a significant role in left ventricular dysfunction.
Hepatic and splenic elastography: are they predictors of recurrence of esophageal varices after complete eradication?
Authors: Daniela Reis, Filipe de Sousa Damião, Ricardo Crespo, Carlos Noronha Ferreira, Luís Carrilho-Ribeiro, Maria Fatima Serejo L Silva, Rui Tato Marinho
Journal: Journal of Hepatology (2020)
Clinical Hypertension
Authors: Frank A. Howard
Journal: JAMA (1983)

Although Professor Kaplan says in the preface that perhaps he may be foolhardy writing this medical book almost single-handedly, he is not. He has done an admirable job. This edition, completed a little over four years since the last, updates the reader from the author's "twelve file cabinets of reprints" on the subject. A splendid chapter on "Hypertension in Childhood and Adolescence" is written by Professor of Pediatrics Ellin Lieberman. The first chapter gives an overview establishing the importance of the subject. The chapters on primary (essential) hypertension and its therapy take up almost half the book. Extensive information about pathophysiology is presented in each chapter. Comprehensive coverage of each of the forms of hypertension is evident in the subsequent chapters with many references at the end of each chapter. Under therapy, old subjects such as rice diets are mentioned, as well as new therapy such as calcium entry blockers.
Abstract O.66: Exercise Response in Children and Adolescents Late After Kawasaki Disease According to Early Coronary Status
Authors: Nagib Dahdah, Hugo Gravel, Daniel Curnier, Frédéric Dallaire, Anne Fournier, Michael Portman
Journal: Circulation (2015)

Background: Cardiovascular sequelae after Kawasaki disease (KD) are typically linked to coronary artery aneurysms. This post-hoc analysis describes response to exercise challenge late after KD to determine response according to coronary artery status. Methods: Bruce treadmill testing was performed under an international trail in 117 KD without coronary complications (NS-KD) and 133 with coronary artery aneurysm (CAA-KD). Endurance time, heart rate, systolic and diastolic blood pressure were assessed at rest, at each treadmill stage, peak exercise and recovery. The presence of myocardial perfusion defects was assessed by Tc-99m sestamibi SPECT imaging. Results: Endurance time was similar between groups (11.3 ± 2.6 min vs11.0 ± 2.6 min, NS-KD vs CAA-KD; p=0.343). There were similar responses in all investigated parameters as well (table 1) (p=0.075-0.942). The prevalence of myocardial perfusion defects was comparable in both groups (22.2% in NS-KD and 16.5% in CAA-KD; p=0.255), but predicted lower heart rate at 1-min recovery as well as lower diastolic blood pressure at 1-min and 5-min recovery in patients with abnormal Summed Stress Score &gt; 3 (p = 0.017-0.042).; reversible defects in 12.8% of NS-KD and 11.3% of CAA-KD (p=0.708). Conclusion: Compared to KD patients without CA involvement, the presence of coronary aneurysms at the sub-acute phase does not induce a differential effect on exercise parameters. In contrast, exercise induced myocardial perfusion defect late after the onset of KD correlates with abnormal recovery parameters. These data suggest that the exercise performance alone is unlikely to discriminate patients with or without coronary artery sequelae.
Sequential Measurements of Bone Lead Content by L X-Ray Fluorescence in CaNa 2 EDTA-Treated Lead-Toxic Children
Authors: John F. Rosen, Morri E. Markowitz, Polly E. Bijur, Sarah T. Jenks, Lucian Wielopolski, John A. Kalef-Ezra, Daniel N. Slatkin
Journal: Environmental Health Perspectives (1991)
Neonatal Lessons
Authors: Jon F. Watchko
Journal: JAMA (2006)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Improvement in 5-Year Survival Rates for the Most Common Types of Cancer, 1975-2012
Authors: Epidemiology Working Group Steering Committee, Ovarian Cancer Association Consortium Members of the EWG SC, in alphabetical order:, Jennifer A. Doherty, Allan Jensen, Linda E. Kelemen, Celeste L. Pearce, Elizabeth Poole, Joellen M. Schildkraut, Kathryn L. Terry, Shelley S. Tworoger, Penelope M. Webb, Nicolas Wentzensen
Journal: JNCI Journal of the National Cancer Institute (2017)

With recent ovarian cancer screening studies showing no clinically significant mortality benefit, preventing this disease, identifying high-risk populations, and extending survival remain priorities. However, several challenges are impeding progress in ovarian cancer research. With most studies capturing exposure information from 10 or more years ago, evaluation of how changing patterns of exposures, such as new oral contraceptive formulations and increased intrauterine device use, might influence ovarian cancer risk and survival is difficult. Risk factors for ovarian cancer should be evaluated in the context of tumor histotypes, which have unique molecular features and cells of origin; this is a task that requires large collaborative studies to achieve meaningful sample sizes. Importantly, identification of novel modifiable risk factors, in addition to those currently known to reduce risk (eg, childbearing, tubal ligation, oral contraceptive use), is needed; this is not feasibly implemented at a population level. In this Commentary, we describe important gaps in knowledge and propose new approaches to advance epidemiologic research to improve ovarian cancer prevention and survival, including updated classification of tumors, collection of data on changing and novel exposures, longer follow-up on existing studies, evaluation of diverse populations, development of better risk prediction models, and collaborating prospectively with consortia to develop protocols for new studies that will allow seamless integration for future pooled analyses.
Standardized criteria for required palliative care consultation on the solid tumor oncology service.
Authors: Kerin B. Adelson, Julia Paris, Cardinale B. Smith, Jay Horton, R. Sean Morrison
Journal: Journal of Clinical Oncology (2014)

6623 Background: Studies have shown that for patients with advanced cancer, integration of Palliative Care (PC) is associated with improved symptom control, clearer understanding of prognosis, lower utilization of health care resources, and increased hospice use. The 2012 ASCO guidelines call for incorporation of PC for any patient with metastatic cancer and/or high symptom burden. Despite a top-rated PC division at Mount Sinai, our Solid Tumor (ST) Division utilized PC and hospice less than other centers. Our inpatient ST service demonstrated poor quality metrics. Our 2011-2012 UHC statistics were: mortality index, 1.35 (target <1), 30-day readmission rate, 21.7%, (target < 10.3%) and length of stay (LOS) index, 1.23 (target <1). We hypothesized that implementing standardized criteria for PC consultation would improve these metrics. Methods: During this 3-month pilot, criteria for PC consultation included patients with one or more of the following: stage IV disease, Stage III lung or pancreatic cancer, hospitalization within prior 30 days, >7 day hospitalization, uncontrolled symptoms (pain, nausea, dyspnea, delirium, distress). We looked at two baseline groups for comparison: 1) patients who met eligibility in a six week period prior to the intervention 2) For UHC index data, we used the hospital dashboard average over a 1-year period prior to the intervention. Primary outcomes were: hospice utilization, ST mortality index, 30-day readmission rate and LOS. Results: Comparing group 1 to the pilot group, palliative care consultation doubled from 41% to 82%, 30-day readmission decreased from 36% to 17% (p = 0.022), and hospice utilization increased from 14% to 25% (p = 0.146). UHC data (Group 2 vs. Pilot) showed: mortality index improved (1.35 to 0.59) and 30-day readmission rates decreased (21.7% to 13.5%, p = 0.026). LOS was unchanged (1.23 to 1.25). Conclusions: Mandating palliative care consults for patients at the highest risk for in hospital death and readmission improved hospice utilization, 30-day readmission, oncology service mortality and adherence with ASCO guidelines. Mount Sinai has funded an extra palliative care team; use of these criteria have become our standard of care.
Die Therapie der Wiener Spezialärzte.
Journal: JAMA (1930)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Expression of progesterone induced blocking factor (PIBF) by human cell lines
Authors: M. D. Srivastava, J. H. Check, J. Szekeres-Bartho
Journal: Journal of Clinical Oncology (2004)

3191 Background: PIBF, synthesized by gamma delta T cells exposed to progesterone, acts as an inhibitor of natural killer cells at the maternal-fetal interface. NK cells are also critical to host antitumor defense. PIBF expression by malignant cells could allow evasion from the immune system. The role of PIBF in human cancer remains unknown. Methods: We examined PIBF expression by human cell lines using immunohistochemistry and RT-PCR. All cell lines were maintained in RPMI 1640 5% fetal calf serum without antibiotics at 37oC in a 5% CO2 incubator. Cells in log phase growth with greater than 95% viability were stained with anti-PIBF antibody and DAKO Rabbit EnVision Plus kit according to their protocol. RNA extracted by Qiagen kit, was treated with DNAse I and RNAse inhibitor, followed by heating. RT step using Superscript II from Invitrogen according to their protocol was followed by PCR amplification of cDNA for 40 cycles using Taq polymerase and primers for PIBF (accession number AF330046 L: 5'- CCT-GCG-TGA-CTT-TGA-GTT-GA-3'; R: 5'-CTG-TCA-GCT-GCT-TCA-GTT-GG-3'). Expected product size was 206 bp. GAPDH served as positive control. The PCR products were separated by agarose gel electrophoresis, visualized by ethidium bromide staining, and photographed. Results: All cell lines tested expressed PIBF mRNA: T cell lines: SRIK-NKL, MOT, HUT 102, HUT 78, HTLV1+transformed CD8+ cell line, SRID-TL, JURKAT, SRIA-TL, SRIP-TL, CEM; Myeloid lineage: THP-1,U937, K562, HL60, SRIS-EOSL, ML-1, HEL; B cell lineage: T-PLL, R-CLL, 729pH6neo, SRIH-B(ATL), U266, 8226; epithelial: MDE, KATO-3, CaCo-2, MeWo, MCF-7; fibroblast: BG9; G-CSF mobilized CD34+ normal cells . PCR without RT step gave no product. In addition, SRIK-NKL, MOT, U937, HL60, R-CLL, MD-B, 729pH6neo, SRIH-B (ATL), T-PLL, and MeWo were stained for protein. Only SRIK-NKL (natural killer), U937 (monoblast), HL60 (myeloid), and T-PLL (B cell) were positive by IHC. Conclusions: PIBF mRNA was widely expressed, and protein was detected in 4/10 leukemic lines tested indicating a role for PIBF in some malignancies and suggesting PIBF as a novel target for therapy. No significant financial relationships to disclose.
SOME OBJECTIONS TO THE PASTEURIZATION OF MILK
Journal: JAMA (1905)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Gut Microbiome-Based Metagenomic Signature for Non-invasive Detection of Advanced Fibrosis in Human Nonalcoholic Fatty Liver Disease
Authors: Rohit Loomba, Victor Seguritan, Weizhong Li, Tao Long, Niels Klitgord, Archana Bhatt, Parambir Singh Dulai, Cyrielle Caussy, Richele Bettencourt, Sarah K. Highlander, Marcus B. Jones, Claude B. Sirlin, Bernd Schnabl, Lauren Brinkac, Nicholas Schork, Chi-Hua Chen, David A. Brenner, William Biggs, Shibu Yooseph, J. Craig Venter, Karen E. Nelson
Journal: Cell Metabolism (2019)